WH002

· Beijing Wehand-Bio Pharmaceutical Co., Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for WH002, covering 2026-01-20 to 2026-01-20. Get the full timeline:

Most recent: Clinical Trial Update: Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer [Phase 1]